Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
N/A
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.08
Trade Value (12mth)
AU$3,718.00
1 week
8.57%
1 month
11.76%
YTD
15.15%
1 year
0%
All time high
0.54
EPS 3 yr Growth
-109.90%
EBITDA Margin
N/A
Operating Cashflow
$0m
Free Cash Flow Return
0.90%
ROIC
6.50%
Interest Coverage
N/A
Quick Ratio
58.90
Shares on Issue (Fully Dilluted)
145m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
06 November 24 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
29 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
02 October 24 |
Letter to Shareholders and Proxy Form
×
Letter to Shareholders and Proxy Form |
02 October 24 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
29 August 24 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
29 August 24 |
2024 Annual Report & Appendix 4E
×
2024 Annual Report & Appendix 4E |
19 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
10 July 24 |
Notice of Release of Escrowed Securities
×
Notice of Release of Escrowed Securities |
11 June 24 |
NSB Completes PRE-IND Meeting with US FDA on EmtinB
×
NSB Completes PRE-IND Meeting with US FDA on EmtinB |
29 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
08 April 24 |
Notification of cessation of securities - NSB
×
Notification of cessation of securities - NSB |
02 April 24 |
Appointment of Executive Director & FDA Pre-Ind Meeting
×
Appointment of Executive Director & FDA Pre-Ind Meeting |
20 March 24 |
NSB Receives A$2.2M Research & Development Tax Refund
×
NSB Receives A$2.2M Research & Development Tax Refund |
27 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
06 February 24 |
Company Secretary Appointment/Resignation
×
Company Secretary Appointment/Resignation |
31 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
15 January 24 |
Notification of cessation of securities - NSB
×
Notification of cessation of securities - NSB |
27 December 23 |
Expiry of Options
×
Expiry of Options |
07 December 23 |
Final Director's Interest Notice - Rennie
×
Final Director's Interest Notice - Rennie |
05 December 23 |
Final Director's Interest Notice - Quantrill
×
Final Director's Interest Notice - Quantrill |
05 December 23 |
Initial Director's Interest Notice - Keating
×
Initial Director's Interest Notice - Keating |
05 December 23 |
Changes to NSB Board
×
Changes to NSB Board |
01 December 23 |
Resignation of CEO
×
Resignation of CEO |
30 November 23 |
Results of Meeting
×
Results of Meeting |
30 November 23 |
Chair's address to shareholders & AGM presentation
×
Chair's address to shareholders & AGM presentation |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.